Dr Daniel Mahony

Mahony will continue as the UK government’s Life Sciences Investment Envoy

The Department for Science, Innovation and Technology has announced that Dr Daniel Mahony will continue as the UK government’s Life Sciences Investment Envoy.

Mahony has more than 25 years of experience in global healthcare investment and has served as the government’s Envoy since 2022, supporting access to finance for the UK life sciences sector.

He is currently a Senior Partner in Growth Investments at Novo Holdings, Chair of the UK BioIndustry Association, and a Non-Executive Director at both the Wellcome Sanger Institute and Oxford Nanopore Technologies.

He also previously co-founded the healthcare business unit at Polar Capital and was formerly a Senior Research Analyst at Morgan Stanley and an Analyst at ING Barings Furman Selz.

Mahony said: “Innovative life sciences and biotech companies have some unique characteristics, including long research and development timelines and high capital requirements, which mean they need specific focus within the wider pension reforms.

“I am looking forward to working with the Chancellor and ministers to ensure the UK is the best place for life science companies to start, scale and stay.”

Science Minister, Lord Patrick Vallance, added: “Dr Mahony’s ongoing work will help to boost the capital available to UK life sciences companies to help them scale and succeed, for the benefit of our economy and for patients.”